Stirling expert panel consensus algorithm for the pharmacological management of allergic rhinitis3

In 2015, a multi-professional group of clinicians met in Stirling, Scotland, to development a simplified allergic rhinitis (AR) treatment algorithm for use in primary and secondary care, incorporating current knowledge and recently available treatments.

Promoting AR management in primary care

The primary objective of the panel was to promote better management of AR patients, improve diagnosis and treatment in primary care and to facilitate transition of difficult-to-treat patients into secondary care. Adherence to this care pathway has the potential to reduce AR management costs in the UK by avoiding unnecessary treatments and investigations, and avoiding the need for costly referrals to secondary care for the majority of AR cases.

SUMMARY OF RECOMMENDATIONS FOR DYMISTA®3
MANAGEMENT IN PRIMARY CARE

The combination of intranasal azelastine hydrochloride and fluticasone propionate in a single device (Dymista® [AZ/FP]) may be used second line after failure of topical intranasal corticosteroids (INCS) after checking for correct use and compliance with the medication. If incorrect use or non-compliance is found, re-education followed by repeat trial of topical INCS is recommended before AZ/FP (single device) prescription.

AZ/FP (single device) may be used first line in certain cases in which the GP considers that monotherapy is more likely to fail, if they consider it warranted in their professional opinion, in accordance with the labelled product indication.

In the event of treatment failure on second-line AZ/FP (single device) in primary care, and correct use of medication and compliance have been checked, along with confirmation of the diagnosis, referral to secondary care is recommended for further investigations.

In secondary care, the consensus group considers that AZ/FP (single device) could be used as a first-line alternative to topical INCS in patients with moderate-severe symptoms (see figure below).

Dymista®’s place in therapy in A: primary care, and B: secondary care, is indicated
in the following treatment algorithms1
PRIMARY CARE
SECONDARY CARE

Abbreviations

AH: anti-histamine; AZE: azelastine; IgE: immunoglobulin E; INCS: intranasal corticosteroid; LTRA: leukotriene receptor antagonist; OAH: oral antihistamine; OC: oral corticosteroid; Rx: treatment; SPT: skin prick test; Sx: symptoms.

*You may consider the addition of an OAH to INCS. However, scientific evidence shows that adding an OAH to INCS provides no additional benefit over INCS alone.

Adapted from Lipworth B, et al. 2017.3

References

The website you are trying to access is designed for healthcare professionals in the UK, the content is not designed for the general public.

Are you a UK healthcare professional?

YES
NO